Using Value-of-Information Methods when the Disease Is Rare and the Treatment Is Expensive-The Example of Hemophilia A

被引:15
作者
Abrahamyan, Lusine [1 ]
Willan, Andrew R. [2 ,3 ]
Beyene, Joseph [2 ,3 ,4 ,5 ,6 ]
Mclimont, Marjorie [2 ]
Blanchette, Victor [2 ,6 ]
Feldman, Brian M. [2 ,3 ,4 ,7 ]
机构
[1] Univ Toronto, Toronto Hlth Econ & Technol Assessment Collaborat, Toronto, ON, Canada
[2] SickKids Res Inst, Child Hlth Evaluat Sci Program, Toronto, ON M5G 1X8, Canada
[3] Univ Toronto, Dalla Lana Sch Publ Hlth, Toronto, ON, Canada
[4] Univ Toronto, Inst Hlth Policy Management & Evaluat, Toronto, ON, Canada
[5] McMaster Univ, Dept Clin Epidemiol & Biostat, Hamilton, ON, Canada
[6] Hosp Sick Children, Div Hematol Oncol, Toronto, ON M5G 1X8, Canada
[7] Hosp Sick Children, Dept Paediat, Div Rheumatol, Toronto, ON M5G 1X8, Canada
基金
英国医学研究理事会; 加拿大自然科学与工程研究理事会;
关键词
expected value of sample information; hemophilia; children; prophylaxis; costs; HEALTH-TECHNOLOGY-ASSESSMENT; EXPECTED VALUE; CLINICAL-TRIAL; DECISION-MAKING; PRIMARY PROPHYLAXIS; DEMAND TREATMENT; ORPHAN DRUGS; SAMPLE-SIZE; BOYS; OUTCOMES;
D O I
10.1007/s11606-014-2880-3
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
100404 [儿少卫生与妇幼保健学];
摘要
BACKGROUND: Hemophilia A is a rare, sex-linked genetic disorder treated with intravenous administration of factor VIII (FVIII) to prevent bleeding; however, approaches vary across and within countries. Value-of-information (VOI) methods identify situations in which the cost-benefit evidence is sufficient to adopt one treatment strategy over another; when the evidence is insufficient, VOI methods provide the optimal sample size for additional research. OBJECTIVE: The objective of the study was to use VOI methods in a cost-benefit decision context to evaluate the current evidence in support of using (1) alternate day prophylaxis (AP), (2) tailored prophylaxis (TP) or (3) on-demand treatment (OD) with FVIII to prevent arthropathy in children with severe hemophilia A. METHODS: To apply VOI methods, several parameters such as incidence, time horizon for the decision, costs, and threshold values to avoid MRI-detected joint damage or arthropathy were defined. Two baseline threshold values of willingness to pay for avoiding arthropathy-$200,000 and $400,000-were selected for comparing the treatment strategies. RESULTS: For threshold values<$200,000, OD had a higher expected net benefit than either prophylaxis strategy, and the evidence was sufficient for its adoption. For threshold values>$400,0,00 prophylaxis strategies had higher expected net benefit; however, a new trial with 38 patients per arm was needed to compare AP and TP, yielding an expected net gain of over $17 million. In sensitivity analyses, the results were robust to assumptions regarding discount rate, trial fixed and variable costs, enrollment fraction, and the time horizon. CONCLUSIONS: In rare diseases, evidence is often scarce and insufficient for decision making. In considering the funding of new research and patient reimbursement in rare diseases, VOI methodology may provide more relevant determinations of the value and costs of additional research, compared to standard frequentist methods.
引用
收藏
页码:S767 / S773
页数:7
相关论文
共 38 条
[1]
Expected value of sample information calculations in medical decision modeling [J].
Ades, AE ;
Lu, G ;
Claxton, K .
MEDICAL DECISION MAKING, 2004, 24 (02) :207-227
[2]
A LONGITUDINAL-STUDY OF ORTHOPEDIC OUTCOMES FOR SEVERE FACTOR-VIII-DEFICIENT HEMOPHILIACS [J].
ALEDORT, LM ;
HASCHMEYER, RH ;
PETTERSSON, H ;
EIBL, H ;
GILBERT, M ;
HILGARTNER, M ;
KUNSHACK, M ;
LARRIEU, MJ ;
LEVINE, P .
JOURNAL OF INTERNAL MEDICINE, 1994, 236 (04) :391-399
[3]
Treatment of haemophilia A and B and von Willebrand's disease: summary and conclusions of a systematic review as part of a Swedish health-technology assessment [J].
Berntorp, E. ;
Astermark, J. ;
Baghaei, F. ;
Bergqvist, D. ;
Holmstrom, M. ;
Ljungberg, B. ;
Norlund, A. ;
Palmblad, J. ;
Petrini, P. ;
Stigendal, L. ;
Sawe, J. .
HAEMOPHILIA, 2012, 18 (02) :158-165
[4]
The irrelevance of inference: a decision-making approach to the stochastic evaluation of health care technologies [J].
Claxton, K .
JOURNAL OF HEALTH ECONOMICS, 1999, 18 (03) :341-364
[5]
Current co-ordinated activities of the PEDNET (European Paediatric Network for Haemophilia Management) [J].
Donadel-Claeyssens, S .
HAEMOPHILIA, 2006, 12 (02) :124-127
[6]
Assessing the economic challenges posed by orphan drugs [J].
Drummond, Michael F. ;
Wilson, David A. ;
Kanavos, Panos ;
Ubel, Peter ;
Rovira, Joan .
INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE, 2007, 23 (01) :36-42
[7]
Time and expected value of sample information wait for no patient [J].
Eckermann, Simon ;
Willan, Andrew R. .
VALUE IN HEALTH, 2008, 11 (03) :522-526
[8]
Expected value of information and decision making in HTA [J].
Eckermann, Simon ;
Willan, Andrew R. .
HEALTH ECONOMICS, 2007, 16 (02) :195-209
[9]
Health technology assessment and haemophilia [J].
Farrugia, A. ;
O'Mahony, B. ;
Cassar, J. .
HAEMOPHILIA, 2012, 18 (02) :152-157
[10]
Feldman B M, 2007, Haemophilia, V13, P745, DOI 10.1111/j.1365-2516.2007.01542.x